The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | HRQoL with belantamab mafodotin treatment in patients with R/R myeloma in the DREAMM-7 trial
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the health-related quality of life (HRQoL) of patients with relapsed/refractory (R/R) multiple myeloma receiving belantamab mafodotin in the DREAMM-7 trial (NCT04246047). Prof. Lonial highlights that despite concerns about ocular events, the data show that HRQoL improved over time for patients treated with the agent, and the impact of therapy on daily activities was limited. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
